Mark L. Weiss
PhD, Biology, University of Pennsylvania, 1986
Weiss joined the faculty at Kansas State University in 1991. He is co-discoverer of mesenchymal stromal cells within umbilical cord Wharton's jelly, is a Founding Fellow of the Midwest Institute for Comparative Stem Cell Biotechnology and serves as Associate Director of the Terry C. Johnson Center for Basic Cancer Research.
Weiss' research focus is on stem cell biotechnology. His lab successfully produced various stem cell lines such as rat embryonic stem cells and cells derived from umbilical cord or other tissues with the intent of using this technology to advance cellular therapy and regenerative medicine. His lab is focused upon producing promising cellular therapeutics for regenerative medicine. For example, mesenchymal stromal cells have been tested in a variety of rodent preclinical disease models including neurodegenerative diseases such as Parkinson's disease, heart disease such as myocardial infarction, and cancer. Based upon the immune properties of Wharton' s jelly derived mesenchymal stromal cells, the lab is working towards clinical trials with colleagues at Kansas State University, the University of Kansas and University of Minnesota.
In addition, the Weiss lab focuses upon the mechanisms of pluripotency in rat embryonic stem cells. In this area the focus is to efficiently produce new rat models of human disease using gene targeting in rat embryonic stem cells. Till date, the lab has produced chimeric rats using the techniques described by our collaborator, Dr. Qilong Ying (USC), and a variety of tools for quality control and validation.
AP 747 Veterinary Physiology II
AP 850 Stem Cell Techniques
Wharton's Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report. Lopez Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, Borgarelli M, Weiss ML. Curr Stem Cell Res Ther. 2013 Jan 1;8(1):46-59. PMID: 23270633
A focused microarray for screening rat embryonic stem cell lines. Hong J, He H, Bui P, Ryba-White B, Rumi MA, Soares MJ, Dutta D, Paul S, Kawamata M, Ochiya T, Ying QL, Rajanahalli P, Weiss ML. Stem Cells Dev. 2013 Feb 1;22(3):431-43. doi: 10.1089/scd.2012.0279. Epub 2012 Sep 28. PMID: 22889370
Derivation and Characterization of Embryonic Stem Cells Lines Derived from Transgenic Fischer 344 and Dark Agouti Rats. J. Hong, H. He, and M.L. Weiss. Stem Cells and Development. Published Oct 13, 2011 PMID: 21995453
Evaluating the impact of oxygen concentration and plating density on human Wharton's jelly-derived mesenchymal stromal cells. Y. López, K. Seshareddy, E. Trevino, J. Cox, and M.L. Weiss. The Open Tissue Engineering and Regenerative Medicine Journal, in press.
Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review). McGuirk JP, Weiss ML. Placenta. 2011 Jun 7. PMID:21658764
Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS). Parolini O, Alviano F, Betz AG, Bianchi DW, Götherström C, Manuelpillai U, Mellor AL, Ofir R, Ponsaerts P, Scherjon SA, Weiss ML, Wolbank S, Wood KJ, Borlongan CV. Placenta. 2011 May 14. PMID:21575989
Xenogeneic transplantation of equine testicular cells into seminiferous tubules of immunocompetent rats. Ferrer MS, Lutjemeier BJ, Koopman T, Pierucci-Alves F, Weiss ML. Theriogenology. 2011 Apr 15;75(7):1258-64. PMID:21316749
Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Wang L, Ott L, Seshareddy K, Weiss ML, Detamore MS. Regen Med. 2011 Jan;6(1):95-109. PMID:21175290
A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS. Tissue Eng Part A. 2009 Aug;15(8):2259-66. PMID:19260778
Effect of initial seeding density on human umbilical cord mesenchymal stromal cells for fibrocartilage tissue engineering. Wang L, Seshareddy K, Weiss ML, Detamore MS. Tissue Eng Part A. 2009 May;15(5):1009-17. PMID:18759671
Immune properties of human umbilical cord Wharton's jelly-derived cells. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, Troyer D, McIntosh KR. Stem Cells. 2008 Nov;26(11):2865-74. PMID:18703664
Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Rachakatla RS, Pyle MM, Ayuzawa R, Edwards SM, Marini FC, Weiss ML, Tamura M, Troyer D. Cancer Invest. 2008 Aug;26(7):662-70. PMID:18608205
Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord. Seshareddy K, Troyer D, Weiss ML. Methods Cell Biol. 2008;86:101-19. PMID:18442646
Wharton's jelly-derived cells are a primitive stromal cell population. Troyer DL, Weiss ML. Stem Cells. 2008 Mar;26(3):591-9. PMID:18065397
Stem cells in the umbilical cord. Weiss ML, Troyer DL. Stem Cell Rev. 2006;2(2):155-62. PMID:17237554